Clinical Trials
21 trialsNCT03349450 2026-05-06
SPiReL
Sunnybrook Health Sciences Centre
Phase 2 Completed
NCT06984328 2026-05-05
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
Genmab
Phase 2 Active not recruiting
NCT03618550 2026-04-16
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT05669846 2026-03-23
Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed/Refractory (R/R) PD-L1 Positive NSCLC
University of Pittsburgh
Phase 2 Recruiting
NCT04268277 2026-02-27
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY
University of Ulm
Phase 2 Terminated
NCT06052839 2026-02-09
Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
University of Pittsburgh
Phase 2 Recruiting
NCT03082534 2026-01-28
Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
University of California, San Diego
Phase 2 Completed
NCT04220866 2025-10-29
MK-1454-002
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT03383094 2025-10-07
Chemoradiation vs Immunotherapy and Radiation for Head and Neck Cancer
University of California, San Diego
Phase 2 Active not recruiting
NCT05263492 2025-10-02
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
Virginia Commonwealth University
Phase 2 Terminated
NCT03179930 2025-07-23
Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05313243 2025-03-20
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
Yale University
Phase 2 Recruiting
NCT06670911 2025-02-24
ACCESS-I
Instituto Nacional de Cancer, Brazil
Phase 2 Recruiting
NCT03385226 2024-12-09
PORT
University College, London
Phase 2 Active not recruiting
NCT04713514 2024-12-02
TEDOVA
ARCAGY/ GINECO GROUP
Phase 2 Active not recruiting
NCT03630042 2024-11-07
PembroWM
University College, London
Phase 2 Completed
NCT05635344 2024-04-17
A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia
Imperial College London
Phase 2 Recruiting
NCT04510636 2024-03-22
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
University Health Network, Toronto
Phase 2 Recruiting
NCT02440425 2022-10-07
Dose Dense Paclitaxel With Pembrolizumab (MK-3475) in Platinum Resistant Ovarian Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02337491 2020-12-22
Pembrolizumab +/- Bevacizumab for Recurrent GBM
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02492568 2020-08-17
PEMBRO-RT
The Netherlands Cancer Institute
Phase 2 Completed